Jeong Eun Kim

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 5

Top Topics

Circulating Tumor

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Choy
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular cancer therapeutics (2023)
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Choy
Venadaparib is a novel and selective PARP inhibitor with improved physicochemical properties, efficacy, and safety. Molecular cancer therapeutics (2023)
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Choy
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular cancer therapeutics 22 (3) (2023)
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Choy
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular cancer therapeutics 22 (3) (2023)
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Choy
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular cancer therapeutics 22 (3) (2023)